Sales Representatives; Detailing Sample Clauses

Sales Representatives; Detailing. The Parties will discuss and agree upon the exact number of sales representatives that may be allocated to the Party opting-in to [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. Commercialization Opt-In Activities to promote and detail the Licensed Products in the ROW Territory (if Juno opted in), or outside the ROW Territory (if Celgene opted in), provided that the Party opting-in to Commercialization Opt-In Activities will have the right to provide (i) [***], or (ii) [***]. The Party opting-in to Commercialization Opt-In Activities will be [***]. Each Party will be responsible for the activities of its sales representatives, including compliance by its sales representatives with training and detailing requirements. Notwithstanding the foregoing, the Party opting-in to Commercialization Opt-In Activities [***] such Licensed Product in accordance with the terms of this License Agreement and applicable Law in the relevant countries. If the Commercialization Lead Party raises [***] with the Party opting-in to Commercialization Opt-In Activities regarding [***], such other Party will [***].
Sample 1Sample 2Sample 3
AutoNDA by SimpleDocs
Sales Representatives; Detailing. The following provisions shall apply to the activities of sales representatives with respect to Commercialization of Shared Products:
Sample 1Sample 2
Sales Representatives; Detailing. The following provisions shall apply to the activities of sales representatives with respect to Commercialization of Co-Co Products:
Sample 1Sample 2
Sales Representatives; Detailing. The following provisions shall apply to the activities of sales representatives with respect to Commercialization of Co-Co Products: CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.
Sample 1Sample 2
Sales Representatives; Detailing. Each Party will be solely responsible for recruiting, hiring and maintaining its sales force of sales representatives for promotion of the Co-Co Product for U.S. Administration in accordance with its standard procedures and the requirements of this Co-Co Agreement. Each Party will be responsible for the activities of its sales representatives, including compliance by its sales representatives with training and detailing requirements. In particular, each Party will provide its sales representatives assigned to promote the Co-Co Product in the U.S. with the level of oversight, management, direction and sales support with respect to the promotion of Co-Co Product necessary to effectively and efficiently promote the Co-Co Product in accordance with the terms of this Co-Co Agreement and applicable Law. If [***] raises any reasonable concern with [***] regarding [***] of any [***], [***] will address such concerns in a manner consistent with [***], which may include [***].
Sample 1
Sales Representatives; Detailing. The following provisions shall apply to the activities of sales representatives with respect to Commercialization of Juno Program Co-Co Products: [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
Sample 1
Sales Representatives; Detailing. For Celgene Program Co-Co Products in countries in which Juno provides Commercialization support to Celgene, each Party will be solely responsible for recruiting, hiring and maintaining its sales force of sales representatives for promotion of the Celgene Program Co-Co Product in the Territory, in accordance with (i) the share of such activities held by each Party in the applicable countries in the Territory pursuant to Sections 3.1.1 and 3.1.2 and (ii) its standard procedures and the requirements of this Celgene Lead Co-Co Agreement. Each Party shall engage sales representatives having the minimum qualifications set forth in Schedule 3.1.6(b), provided that if Juno has exercised its right to co-Commercialize in the Major EU Market Countries pursuant to Sections 3.1.2 and/or 3.1.3, the sales representatives [***]. The Celgene Co-Co Commercialization Plan will set forth (A) [***], as applicable, consistent with the foregoing, (B) policies and processes for the [***], (D) the [***] sales representatives for Celgene Program Co-Co Products in each Calendar Year, (E) the allocation of [***] between the Parties, (F) development of [***], and (G) coordinating strategies for [***]. If [***] for the North America Territory or the Major EU Market Countries, then [***] will have the right to [***] until such time as [***], and, for clarity, all costs incurred by [***] related to [***]. Each Party will be responsible for the activities of such sales representatives, including compliance by such sales representatives with training and detailing requirements. In particular, each Party will provide its sales representatives assigned to promote the Celgene Program Co-Co Product in such countries with [***] with respect to the promotion of Celgene Program Co-Co Product necessary to [***] [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. the Celgene Program Co-Co Product in accordance with the terms of this Celgene Lead Co-Co Agreement and applicable Law. Each Party agrees that none of its sales representatives involved in the promotion of the Celgene Program Co-Co Product will have any legal or regulatory disqualifications, bars or sanctions. If Celgene [***] regarding the [***] designated to be performed by Juno under this Article 3, [***] will [***] consistent with [***], which may include [***] the Celgene Program Co...
Sample 1
AutoNDA by SimpleDocs

Related to Sales Representatives; Detailing

  • Sales Representatives 22.01 The Employer agree that sales representatives will not per- form work in its stores on items shipped through the warehouse, ex- cept for major promotional periods. In the event that a product line which is currently shipped direct to stores is converted into our xxxx- house, the sales representatives may continue to perform work on these items. Where practicable, the Company shall provide the Union with 4 weeks notice of such conversions.

  • Third Party Services Any services required for or contemplated by the performance of the above-referenced services by the Administrator to be provided by unaffiliated third parties (including independent auditors’ fees and counsel fees) may, if provided for or otherwise contemplated by the Financing Order and if the Issuer deems it necessary or desirable, be arranged by the Issuer or by the Administrator at the direction (which may be general or specific) of the Issuer. Costs and expenses associated with the contracting for such third-party professional services may be paid directly by the Issuer or paid by the Administrator and reimbursed by the Issuer in accordance with Section 2, or otherwise as the Administrator and the Issuer may mutually arrange.

  • Sales Force During the term of this Agreement, Licensee shall maintain a non-exclusive sales force suitable to carry out the purpose of this Agreement.

  • Collaboration Management Promptly after the Effective Date, each Party will appoint a person who will oversee day-to-day contact between the Parties for all matters related to the management of the Collaboration Activities in between meetings of the JSC and will have such other responsibilities as the Parties may agree in writing after the Effective Date. One person will be designated by Merck (the “Merck Program Director”) and one person will be designated by Moderna (the “Moderna Program Director,”) together will be the “Program Directors”. Each Party may replace its Program Director at any time by notice in writing to the other Party. Any Program Director may designate a substitute to temporarily perform the functions of that Program Director by written notice to the other Party. The initial Program Directors will be: For Moderna: [***] For Merck: [***]

  • Development Activities The Development activities referred to in item “b” of paragraph 3.1 include: studies and projects of implementation of the Production facilities; drilling and completion of the Producing and injection xxxxx; and installation of equipment and vessels for extraction, collection, Treatment, storage, and transfer of Oil and Gas. The installation referred to in item “c” includes, but is not limited to, offshore platforms, pipelines, Oil and Gas Treatment plants, equipment and facilities for measurement of the inspected Production, wellhead equipment, production pipes, flow lines, tanks, and other facilities exclusively intended for extraction, as well as oil and gas pipelines for Production Outflow and their respective compressor and pumping stations.

  • Direct Sales The Manager will advise you promptly, on the Offering Date, as to the Securities purchased by you pursuant to the Underwriting Agreement that you will retain for direct sale. At any time prior to the termination of the applicable AAU, any such Securities that are held by the Manager for sale but not sold may, on your request and at the Manager’s discretion, be released to you for direct sale, and Securities so released to you will no longer be deemed held for sale by the Manager. You may allow, and Dealers may reallow, a discount on sales to Dealers in an amount not in excess of the Reallowance set forth in the applicable AAU. You may not purchase Securities from, or sell Securities to, any other Underwriter or Dealer at any discount or concession other than the Reallowance, except with the prior consent of the Manager.

  • Commercialization Activities Within North America, the Parties will use Commercially Reasonable Efforts to Commercialize Licensed Products in the Field. In addition, within North America and subject to Section 2.7.6, the Parties will use Commercially Reasonable Efforts to conduct the Commercialization activities assigned to them pursuant to the Commercialization Plan/Budget, including the performance of detailing in accordance therewith. In conducting the Commercialization activities, the Parties will comply with all Applicable Laws, applicable industry professional standards and compliance policies of Celgene which have been previously furnished to Acceleron, as the same may be updated from time to time and provided to Acceleron. Neither Party shall make any claims or statements with respect to the Licensed Products that are not strictly consistent with the product labeling and the sales and marketing materials approved for use pursuant to the Commercialization Plan/Budget.

  • Manufacturing Services Jabil will manufacture the Product in accordance with the Specifications and any applicable Build Schedules. Jabil will reply to each proposed Build Schedule that is submitted in accordance with the terms of this Agreement by notifying Company of its acceptance or rejection within three (3) business days of receipt of any proposed Build Schedule. In the event of Jabil’s rejection of a proposed Build Schedule, Jabil’s notice of rejection will specify the basis for such rejection. When requested by Company, and subject to appropriate fee and cost adjustments, Jabil will provide Additional Services for existing or future Product manufactured by Jabil. Company shall be solely responsible for the sufficiency and adequacy of the Specifications [***].

  • Contract Sales Price The total consideration provided for in the sales contract for the sale of a Property.

Time is Money Join Law Insider Premium to draft better contracts faster.